These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 25814210)

  • 1. Normal blood catecholamines, recurrent ventricular fibrillation, and "ventricular scar", in a patient with Takotsubo syndrome.
    Madias JE
    Int J Cardiol; 2015 Apr; 185():248. PubMed ID: 25814210
    [No Abstract]   [Full Text] [Related]  

  • 2. Takotsubo cardiomyopathy: Utility of cardiac magnetic resonance to stratify risk for sudden cardiac death.
    Ghafoor A; Janardhanan R
    Int J Cardiol; 2015 Apr; 184():492-493. PubMed ID: 25756575
    [No Abstract]   [Full Text] [Related]  

  • 3. Management of sudden cardiac death in cardiac sarcoidosis using the wearable cardioverter defibrillator.
    Skowasch D; Ringquist S; Nickenig G; Andrié R
    PLoS One; 2018; 13(3):e0194496. PubMed ID: 29566033
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Implantable cardioverter defibrillators in the prevention of sudden cardiac death].
    Bockeria LA; Neminushchiy NM; Mikhaylichenko SI; Novichkov SA; Achkasov EE
    Ter Arkh; 2017; 89(12):103-109. PubMed ID: 29411768
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implantable Cardioverter-Defibrillator Therapy in Arrhythmogenic Right Ventricular Dysplasia/Cardiomyopathy: Predictors of Appropriate Therapy, Outcomes, and Complications.
    Orgeron GM; James CA; Te Riele A; Tichnell C; Murray B; Bhonsale A; Kamel IR; Zimmerman SL; Judge DP; Crosson J; Tandri H; Calkins H
    J Am Heart Assoc; 2017 Jun; 6(6):. PubMed ID: 28588093
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Noninvasive risk stratification prevents sudden death due to paroxysmal atrial fibrillation in hypertrophic cardiomyopathy.
    Limongelli G; Elliott PM; Pacileo G; Sarubbi B; Thaman R; Calabrò P; Vergara P; Iacomino M; Russo MG; Calabrò R
    J Cardiovasc Med (Hagerstown); 2006 Sep; 7(9):711-3. PubMed ID: 16932087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Wearable Cardioverter-Defibrillator in Newly Diagnosed Cardiomyopathy: Treatment on the Basis of Perceived Risk.
    Epstein AE
    J Am Coll Cardiol; 2015 Dec; 66(23):2614-2617. PubMed ID: 26670061
    [No Abstract]   [Full Text] [Related]  

  • 8. Prognostic Benefit of Cardiac Magnetic Resonance Over Transthoracic Echocardiography for the Assessment of Ischemic and Nonischemic Dilated Cardiomyopathy Patients Referred for the Evaluation of Primary Prevention Implantable Cardioverter-Defibrillator Therapy.
    Pontone G; Guaricci AI; Andreini D; Solbiati A; Guglielmo M; Mushtaq S; Baggiano A; Beltrama V; Fusini L; Rota C; Segurini C; Conte E; Gripari P; Dello Russo A; Moltrasio M; Tundo F; Lombardi F; Muscogiuri G; Lorenzoni V; Tondo C; Agostoni P; Bartorelli AL; Pepi M
    Circ Cardiovasc Imaging; 2016 Oct; 9(10):. PubMed ID: 27729359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of the main implantable cardioverter-defibrillator trials and the 2006 Guidelines for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death.
    Proclemer A; Ghidina M
    J Cardiovasc Med (Hagerstown); 2007 May; 8(5):320-3. PubMed ID: 17443096
    [No Abstract]   [Full Text] [Related]  

  • 10. Can QRS scoring predict left ventricular scar and clinical outcomes?
    Rosengarten JA; Scott PA; Chiu OK; Shambrook JS; Curzen NP; Morgan JM
    Europace; 2013 Jul; 15(7):1034-41. PubMed ID: 23493411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk stratification for implantable cardioverter defibrillator therapy: the role of the wearable cardioverter-defibrillator.
    Klein HU; Goldenberg I; Moss AJ
    Eur Heart J; 2013 Aug; 34(29):2230-42. PubMed ID: 23729691
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ventricular Arrhythmias.
    Dresen WF; Ferguson JD
    Cardiol Clin; 2018 Feb; 36(1):129-139. PubMed ID: 29173673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recent developments in the subcutaneous ICD.
    Willcox ME; Prutkin JM; Bardy GH
    Trends Cardiovasc Med; 2016 Aug; 26(6):526-35. PubMed ID: 27079889
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is Takotsubo syndrome one of the causes of sudden cardiac death?
    Madias JE
    Pacing Clin Electrophysiol; 2013 Jul; 36(7):793-4. PubMed ID: 23510209
    [No Abstract]   [Full Text] [Related]  

  • 15. Wearable cardioverter-defibrillator as a bridge to implantable cardioverter-defibrillator treatment.
    Technol Eval Cent Assess Program Exec Summ; 2010 Nov; 25(2):1-5. PubMed ID: 21638938
    [No Abstract]   [Full Text] [Related]  

  • 16. Atrial fibrillation and recurrent ventricular fibrillation during hypokalemia in Brugada syndrome.
    Notarstefano P; Pratola C; Toselli T; Ferrari R
    Pacing Clin Electrophysiol; 2005 Dec; 28(12):1350-3. PubMed ID: 16403168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Is defibrillation testing necessary for implantable transvenous defibrillators?: defibrillation testing is necessary at the time of implantable cardioverter defibrillator implantation.
    Russo AM; Chung MK
    Circ Arrhythm Electrophysiol; 2014 Apr; 7(2):337-46. PubMed ID: 24736423
    [No Abstract]   [Full Text] [Related]  

  • 18. Long-Term Clinical Outcome of Arrhythmogenic Right Ventricular Cardiomyopathy in Individuals With a p.S358L Mutation in TMEM43 Following Implantable Cardioverter Defibrillator Therapy.
    Hodgkinson KA; Howes AJ; Boland P; Shen XS; Stuckless S; Young TL; Curtis F; Collier A; Parfrey PS; Connors SP
    Circ Arrhythm Electrophysiol; 2016 Mar; 9(3):. PubMed ID: 26966288
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of arrhythmias in patients with Takotsubo cardiomyopathy: Is the implantation of permanent devices necessary?
    Stiermaier T; Rommel KP; Eitel C; Möller C; Graf T; Desch S; Thiele H; Eitel I
    Heart Rhythm; 2016 Oct; 13(10):1979-86. PubMed ID: 27298201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention of sudden cardiac deaths in arrhythmogenic right ventricular cardiomyopathy: how to evaluate risk and when to implant a cardioverter-defibrillator?
    Woźniak O; Włodarska EK
    Cardiol J; 2009; 16(6):588-91. PubMed ID: 19950101
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.